70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.117044 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Robbert C A M Gielen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medical Oncology and Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor, Gene Expression Profiling. Die Arbeit nennt 23 Literaturangaben. Gefördert von: KWF Kankerbestrijding.
Abstract (Originalsprache)
BACKGROUND: Adjuvant chemotherapy (ACT) can be safely omitted in patients above 50 years of age with stage I-II hormone receptor positive (HR+) HER2-negative (HER2-) breast cancer and a low-risk 70-gene signature (MammaPrint®). However, the contribution of the 70-gene signature in high-risk subgroups by nodal involvement, grade 3 or larger tumors, has not been reported, which may complicate clinical decision making for these patients. PATIENTS AND METHODS: Patients above 50 years enrolled in the MINDACT trial with primary stage I-II HR + HER2- breast cancer and a clinical high/genomic low-risk were selected for this exploratory analysis. In the MINDACT trial, these patients were randomized at enrollment based on their risk assessment method for the decision to receive ACT or not. Eight-year distant metastasis free survival (DMFS) was the primary endpoint. RESULTS: Median follow-up was 8.7 years. Of the 868 clinical high/genomic low-risk MINDACT patients, 490 (56.5%) patients had tumors larger than 2 cm, 232 (26.7%) had grade 3 tumors and 406 (46.8%) had 1-3 involved lymph nodes. 8-year DMFS in the no ACT group was 87.9% (95%CI: 82.9-91.6%) in patients with tumors larger than 2 cm; 91.3% (95%CI: 84.0-95.4%) with grade 3 tumors and 89.6% (95%CI: 84.2-93.3%) with nodal involvement. Absolute 8-year DMFS benefit for ACT versus no ACT was 1.2%; -2.2% and 0.7% respectively. CONCLUSIONS: This exploratory subgroup analysis of the MINDACT trial confirms the prognostic performance of the 70-gene signature in patients with high-risk features such as larger tumors, grade 3 tumors and 1-3 involved lymph nodes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Medical Oncology and Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.
- European Organization for Research and Treatment of Cancer -EORTC Headquarters, Brussels, Belgium.
- Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
- Breast Surgical Oncology Unit, Clínica Universidad de Navarra, CCUN, Spain.
- Institut Gustave Roussy, Villejuif, France.
- Institut Curie, Paris & Saint-Cloud, Université de Paris, France.
Förderung
- KWF Kankerbestrijding
Zitieren
APA
Gielen, R. C. A. M., Poncet, C., van 't Veer, L. J., Rubio, I. T., Delaloge, S., Pierga, J. Y., Brain, E., Vrijaldenhoven, S., Neijenhuis, P. A., Ignatiadis, M., Viale, G., Cardoso, F., Piccart, M., Rutgers, E. J. T., Kok, M., & Drukker, C. A. (2026). 70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117044
Vancouver
Gielen RCAM, Poncet C, van 't Veer LJ, Rubio IT, Delaloge S, Pierga JY, et al. 70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.117044
BibTeX
@article{Gielen2026,
author = {Gielen, Robbert C A M and Poncet, Coralie and van 't Veer, Laura J and Rubio, Isabel T and Delaloge, Suzette and Pierga, Jean-Yves and Brain, Etienne and Vrijaldenhoven, Suzan and Neijenhuis, Peter A and Ignatiadis, Michail and Viale, Giuseppe and Cardoso, Fatima and Piccart, Martine and Rutgers, Emiel J T and Kok, Marleen and Drukker, Caroline A},
title = {70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.117044}
}
EUVIMED